Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 April 2015Next earnings report:
14 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 22:07:00 GMTDividend
Analysts recommendations
Institutional Ownership
BPMC Latest News
Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion into Germany and the potential for further indication of growth underpin Blueprint's valuation and future revenue projections. Blueprint's investigational pipeline, including drugs like BLU-222 and elenestinib, targets various cancers and mast cell disorders, enhancing long-term growth potential.
Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference Call Participants Marc Frahm - TD Cowen Brad Canino - Stifel Reni Benjamin - Citizens JMP Paul Jeng - Guggenheim Tommie Reerink - Goldman Sachs Derek Archila - Wells Fargo Mike Ulz - Morgan Stanley Ami Fadia - Needham Markus Schweiger - Oppenheimer Peter Lawson - Barclays Laura Prendergast - Raymond James David Lebowitz - Citi Sudan Loganathan - Stephens Operator Good morning. My name is Nadia, and I'll be your conference operator today.
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $2.20 per share a year ago.
-- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- -- On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass. , Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated financial guidance.
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
CAMBRIDGE, Mass. , Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
What type of business is Blueprint Medicines?
Blueprint Medicines Corporation is a precision therapy company specializing in genomic cancer diseases, rare diseases, and cancer immunotherapy. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines Corporation is developing the following drugs: avapritinib - for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263 - an oral potent inhibitor for the treatment of indolent SM and other mast cell diseases; fisogatinib - an oral potent inhibitor currently in phase I clinical trials for the treatment of hepatocellular carcinoma and other drugs for the treatment of rare genomic and tumor diseases.
What sector is Blueprint Medicines in?
Blueprint Medicines is in the Healthcare sector
What industry is Blueprint Medicines in?
Blueprint Medicines is in the Biotechnology industry
What country is Blueprint Medicines from?
Blueprint Medicines is headquartered in United States
When did Blueprint Medicines go public?
Blueprint Medicines initial public offering (IPO) was on 30 April 2015
What is Blueprint Medicines website?
https://www.blueprintmedicines.com
Is Blueprint Medicines in the S&P 500?
No, Blueprint Medicines is not included in the S&P 500 index
Is Blueprint Medicines in the NASDAQ 100?
No, Blueprint Medicines is not included in the NASDAQ 100 index
Is Blueprint Medicines in the Dow Jones?
No, Blueprint Medicines is not included in the Dow Jones index
When was Blueprint Medicines the previous earnings report?
No data
When does Blueprint Medicines earnings report?
The next expected earnings date for Blueprint Medicines is 14 February 2025